Is continuous positive airway pressure (CPAP) effective for treating Upper Airway Resistance Syndrome (UARS)?

CPAP is Effective for UARS and Should Be Offered as First-Line Treatment

Yes, CPAP helps with Upper Airway Resistance Syndrome (UARS) and should be recommended as the primary treatment option, though patient adherence may be challenging.

Evidence for CPAP Efficacy in UARS

The foundational research on UARS directly demonstrates that nasal CPAP eliminates the core pathophysiology and symptoms of this syndrome 1. In the original cohort of 15 UARS patients with severe daytime sleepiness (mean sleep latency 5.1 minutes), CPAP treatment:

• Eliminated daytime sleepiness (sleep latency improved to 13.5 minutes)
• Reduced transient alpha EEG arousals from 31.3 to 8 per hour of sleep
• Abolished the abnormal upper airway resistance that triggers these arousals

This mechanism-based efficacy has been consistently confirmed 2, 3, establishing CPAP as the most efficacious therapy for UARS, though with an important caveat about compliance discussed below.

Why CPAP Works in UARS

UARS differs from classic obstructive sleep apnea in that patients experience:

• Repetitive increases in upper airway resistance (not complete obstruction)
• Brief EEG arousals triggered by increasingly negative intrathoracic pressure (averaging -33 cm H2O)
• Minimal to no oxygen desaturation
• Apnea-hypopnea index (AHI) ≤ 5 events/hour

CPAP acts as a pneumatic splint that prevents the progressive narrowing of the upper airway, thereby eliminating the need for escalating respiratory effort and the arousal-inducing negative intrathoracic pressure swings 2.

Practical Implementation

While formal UARS-specific guidelines don't exist, the American Academy of Sleep Medicine guidelines for OSA management 4 provide the framework for PAP therapy initiation, which applies to UARS given the shared upper airway pathophysiology:

• Either auto-adjusting PAP (APAP) or fixed CPAP can be used for ongoing treatment
• Home APAP titration is as effective as in-laboratory titration for most patients
• Close monitoring within the first few weeks is essential to optimize settings and address adherence barriers

For UARS specifically, split-night polysomnography can effectively establish diagnosis and initiate CPAP titration in a single study 5, avoiding the typical 72-day delay between diagnostic testing and treatment initiation.

The Critical Adherence Problem

The major limitation of CPAP in UARS is poor patient compliance 6. This is particularly problematic because:

• UARS patients often lack the classic OSA features (severe obesity, witnessed apneas, profound hypoxemia) that motivate adherence
• Many UARS patients are younger and may have only mild anatomical abnormalities
• The subjective symptoms (fatigue, sleepiness) may not immediately improve, reducing motivation

A 2015 systematic review found that while CPAP remains the mainstay therapy for UARS, its effectiveness is limited by adherence issues 6.

Alternative Treatment Considerations

Mandibular advancement devices (MADs) represent a viable alternative, particularly for patients who cannot tolerate CPAP. Recent evidence shows that after 1.5 years of treatment, MADs significantly decreased stress symptoms in UARS patients with good adherence (6.1 hours/night) and only minor, short-term side effects 7. While the American College of Physicians recommends MADs as an alternative to CPAP for OSA 8, this option is particularly relevant for UARS given the adherence challenges with CPAP.

Clinical Algorithm for UARS Treatment

1. Confirm diagnosis: Respiratory disturbance index >5 events/hour OR flow limitation >30% of sleep time, with AHI ≤5, plus significant sleepiness/fatigue
2. First-line: Initiate CPAP or APAP with intensive education and mask fitting
3. Implement aggressive early monitoring (within 2-4 weeks) to:
   • Review objective adherence data
   • Address mask fit, pressure intolerance, or other barriers
   • Confirm symptom improvement
4. If CPAP fails due to intolerance: Consider MAD as alternative therapy
5. Encourage weight loss in overweight/obese patients as adjunctive therapy 8

Important Caveats

• UARS often goes unrecognized because patients and providers focus on insomnia symptoms while missing covert signs of sleep-disordered breathing 9
• Esophageal manometry remains the gold standard for diagnosis, though less invasive methods are being developed 2
• The distinction between UARS and mild OSA is increasingly recognized as artificial—both represent points on a spectrum of non-hypoxic sleep-disordered breathing 10

The bottom line: CPAP works for UARS when patients use it consistently, but success requires intensive support, early troubleshooting, and willingness to pivot to alternative therapies like MADs when adherence fails.